AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 103 filers reported holding AKERO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 4.79 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,058,000 | +54.8% | 100,000 | +42.9% | 0.70% | +72.8% |
| Q2 2023 | $3,268,300 | +22.0% | 70,000 | 0.0% | 0.40% | -25.0% |
| Q1 2023 | $2,678,200 | -30.2% | 70,000 | 0.0% | 0.54% | -32.9% |
| Q4 2022 | $3,836,000 | -51.0% | 70,000 | -69.6% | 0.80% | -47.1% |
| Q3 2022 | $7,832,000 | +187.7% | 230,000 | -20.2% | 1.52% | +171.6% |
| Q2 2022 | $2,722,000 | -4.1% | 288,058 | +44.0% | 0.56% | -24.1% |
| Q1 2022 | $2,838,000 | +57.8% | 200,000 | +135.3% | 0.74% | +48.2% |
| Q4 2021 | $1,798,000 | -5.4% | 85,000 | 0.0% | 0.50% | -8.8% |
| Q3 2021 | $1,900,000 | -9.9% | 85,000 | 0.0% | 0.55% | -6.0% |
| Q2 2021 | $2,109,000 | -14.5% | 85,000 | 0.0% | 0.58% | -17.6% |
| Q1 2021 | $2,466,000 | +12.4% | 85,000 | 0.0% | 0.70% | +8.1% |
| Q4 2020 | $2,193,000 | -16.2% | 85,000 | 0.0% | 0.65% | -18.5% |
| Q3 2020 | $2,617,000 | +105.7% | 85,000 | +41.7% | 0.80% | +42.9% |
| Q1 2020 | $1,272,000 | – | 60,000 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |